Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analyst Conferences In Brief

This article was originally published in The Gray Sheet

Executive Summary

Stryker: Corin's Cormet hip resurfacing device will be sold by Stryker in the U.S. under a deal struck with the British orthopedic firm, Stryker CFO Dean Bergy said Sept. 8 at the Thomas Weisel Healthcare Tailwinds Conference in Boston. "It's very clear that hip resurfacing has been very well received in many European markets, Australia and Canada. I don't know that the opportunity will be as great in the U.S., but we felt like we'd have to be on the forefront of this technology," Bergy said. Stryker will purchase the hips from Corin on a transfer price basis. Corin has already submitted a PMA application to FDA for the device. If approved, the device will likely compete against Smith & Nephew's Birmingham Hip Resurfacing device, which garnered a positive recommendation from FDA's Orthopaedic & Rehabilitation Devices Panel Sept. 8 in Gaithersburg, Md....

You may also be interested in...



FDA Ortho Panel Will See Second Hip Resurfacing System In Cormet

Corin Group's Cormet will be the second hip resurfacing product to go before an FDA advisory committee when the Orthopaedic and Rehabilitation panel considers the device's PMA next month

FDA Ortho Panel Will See Second Hip Resurfacing System In Cormet

Corin Group's Cormet will be the second hip resurfacing product to go before an FDA advisory committee when the Orthopaedic and Rehabilitation panel considers the device's PMA next month

Women Courted At Orthopedics Meeting; Zimmer Touts “Gender Solutions”

The major orthopedic companies are energetically marketing to women to reverse last year's sluggish knee implant sales growth

Related Content

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel